White label ELPA - ClinicalTrials.eu

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

Recruiting

3 1 1
Investigated diseases:
- Multiple sclerosis
Investigated drugs:
- Ocrelizumab
Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

Recruiting

3 1 1
Investigated drugs:
- Azetukalner
Study on the Safety and Effectiveness of ATTR-01 for Adults with Certain Types of Solid Tumors

Recruiting

2 1 1
Investigated diseases:
- Neoplasm
Investigated drugs:
- ATTR-01
A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Recruiting

3 1
Investigated drugs:
- Mrna-4157
- Pembrolizumab
+2
Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Recruiting

4 1 1 1
Investigated drugs:
- Blinatumomab
- Tocilizumab
+1
Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Recruiting

3 1 1
Investigated drugs:
- Mk-1084
- Durvalumab
+1
Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Recruiting

3 1 1 1
Investigated diseases:
- Acute myeloid leukaemia
Investigated drugs:
+8
Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination

Recruiting

3 1 1 1
Investigated diseases:
- Measles
- Mumps
- Rubella
Investigated drugs:
- RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS
Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Recruiting

4 1 1 1
Investigated diseases:
- Follicular lymphoma
Investigated drugs:
Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Recruiting

2 1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies